Rationale for treatment and study design of tailor: A randomized phase iii trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations

Gabriella Farina, Flavia Longo, Olga Martelli, Ida Pavese, Andrea Mancuso, Luca Moscetti, Roberto Labianca, Alessandro Bertolini, Enrico Cortesi, Antonio Farris, Daniele Fagnani, Maria Cristina Locatelli, Giuseppe Valmadre, Antonio Ardizzoia, Maurizio Tomirotti, Eliana Rulli, Marina Chiara Garassino, Alberto Scanni

Research output: Contribution to journalArticle

Abstract

We present the rationale and study design of the Tarceva Italian Lung Optimization trial phase III, multicenter, open-label, randomized trial on efficacy of second-line therapies in different subgroups of non-small-cell lung cancer (NSCLC) patients identified using molecular and clinical evaluations. To date, we can assume that advanced NSCLC epidermal growth factor receptor (EGFR)-mutated patients benefit from EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib, whereas their role in the treatment of patients who do not have EGFR mutations is controversial. The aim of this study is to assess whether it is possible to optimize second-line treatment in NSCLC patients with absence of EGFR mutations. Moreover, the predictive value of the K-ras mutation, EGFR protein expression, and EGFR gene copy number, as well as a smoking habit and histotype for determining a different effect of erlotinib compared with chemotherapy will be assessed in patients who do not have EGFR mutations. The primary endpoint is overall survival; the secondary endpoints are progression-free survival, response rate, quality of life, and toxicity. We have planned to collect blood samples to identify different prognosis-related polymorphisms and to assess their sensitivity and specificity in the detection of EGFR and K-ras mutations with respect to histologic samples.

Original languageEnglish
Pages (from-to)138-141
Number of pages4
JournalClinical Lung Cancer
Volume12
Issue number2
DOIs
Publication statusPublished - Mar 2011

Fingerprint

docetaxel
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
Therapeutics
erbB-1 Genes
Gene Dosage
Erlotinib Hydrochloride
Protein-Tyrosine Kinases
Disease-Free Survival
Habits
Survival Rate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Rationale for treatment and study design of tailor : A randomized phase iii trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. / Farina, Gabriella; Longo, Flavia; Martelli, Olga; Pavese, Ida; Mancuso, Andrea; Moscetti, Luca; Labianca, Roberto; Bertolini, Alessandro; Cortesi, Enrico; Farris, Antonio; Fagnani, Daniele; Cristina Locatelli, Maria; Valmadre, Giuseppe; Ardizzoia, Antonio; Tomirotti, Maurizio; Rulli, Eliana; Chiara Garassino, Marina; Scanni, Alberto.

In: Clinical Lung Cancer, Vol. 12, No. 2, 03.2011, p. 138-141.

Research output: Contribution to journalArticle

Farina, G, Longo, F, Martelli, O, Pavese, I, Mancuso, A, Moscetti, L, Labianca, R, Bertolini, A, Cortesi, E, Farris, A, Fagnani, D, Cristina Locatelli, M, Valmadre, G, Ardizzoia, A, Tomirotti, M, Rulli, E, Chiara Garassino, M & Scanni, A 2011, 'Rationale for treatment and study design of tailor: A randomized phase iii trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations', Clinical Lung Cancer, vol. 12, no. 2, pp. 138-141. https://doi.org/10.1016/j.cllc.2011.03.008
Farina, Gabriella ; Longo, Flavia ; Martelli, Olga ; Pavese, Ida ; Mancuso, Andrea ; Moscetti, Luca ; Labianca, Roberto ; Bertolini, Alessandro ; Cortesi, Enrico ; Farris, Antonio ; Fagnani, Daniele ; Cristina Locatelli, Maria ; Valmadre, Giuseppe ; Ardizzoia, Antonio ; Tomirotti, Maurizio ; Rulli, Eliana ; Chiara Garassino, Marina ; Scanni, Alberto. / Rationale for treatment and study design of tailor : A randomized phase iii trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. In: Clinical Lung Cancer. 2011 ; Vol. 12, No. 2. pp. 138-141.
@article{ef11fb1b065842d38a13db0d161cad61,
title = "Rationale for treatment and study design of tailor: A randomized phase iii trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations",
abstract = "We present the rationale and study design of the Tarceva Italian Lung Optimization trial phase III, multicenter, open-label, randomized trial on efficacy of second-line therapies in different subgroups of non-small-cell lung cancer (NSCLC) patients identified using molecular and clinical evaluations. To date, we can assume that advanced NSCLC epidermal growth factor receptor (EGFR)-mutated patients benefit from EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib, whereas their role in the treatment of patients who do not have EGFR mutations is controversial. The aim of this study is to assess whether it is possible to optimize second-line treatment in NSCLC patients with absence of EGFR mutations. Moreover, the predictive value of the K-ras mutation, EGFR protein expression, and EGFR gene copy number, as well as a smoking habit and histotype for determining a different effect of erlotinib compared with chemotherapy will be assessed in patients who do not have EGFR mutations. The primary endpoint is overall survival; the secondary endpoints are progression-free survival, response rate, quality of life, and toxicity. We have planned to collect blood samples to identify different prognosis-related polymorphisms and to assess their sensitivity and specificity in the detection of EGFR and K-ras mutations with respect to histologic samples.",
author = "Gabriella Farina and Flavia Longo and Olga Martelli and Ida Pavese and Andrea Mancuso and Luca Moscetti and Roberto Labianca and Alessandro Bertolini and Enrico Cortesi and Antonio Farris and Daniele Fagnani and {Cristina Locatelli}, Maria and Giuseppe Valmadre and Antonio Ardizzoia and Maurizio Tomirotti and Eliana Rulli and {Chiara Garassino}, Marina and Alberto Scanni",
year = "2011",
month = "3",
doi = "10.1016/j.cllc.2011.03.008",
language = "English",
volume = "12",
pages = "138--141",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Rationale for treatment and study design of tailor

T2 - A randomized phase iii trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations

AU - Farina, Gabriella

AU - Longo, Flavia

AU - Martelli, Olga

AU - Pavese, Ida

AU - Mancuso, Andrea

AU - Moscetti, Luca

AU - Labianca, Roberto

AU - Bertolini, Alessandro

AU - Cortesi, Enrico

AU - Farris, Antonio

AU - Fagnani, Daniele

AU - Cristina Locatelli, Maria

AU - Valmadre, Giuseppe

AU - Ardizzoia, Antonio

AU - Tomirotti, Maurizio

AU - Rulli, Eliana

AU - Chiara Garassino, Marina

AU - Scanni, Alberto

PY - 2011/3

Y1 - 2011/3

N2 - We present the rationale and study design of the Tarceva Italian Lung Optimization trial phase III, multicenter, open-label, randomized trial on efficacy of second-line therapies in different subgroups of non-small-cell lung cancer (NSCLC) patients identified using molecular and clinical evaluations. To date, we can assume that advanced NSCLC epidermal growth factor receptor (EGFR)-mutated patients benefit from EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib, whereas their role in the treatment of patients who do not have EGFR mutations is controversial. The aim of this study is to assess whether it is possible to optimize second-line treatment in NSCLC patients with absence of EGFR mutations. Moreover, the predictive value of the K-ras mutation, EGFR protein expression, and EGFR gene copy number, as well as a smoking habit and histotype for determining a different effect of erlotinib compared with chemotherapy will be assessed in patients who do not have EGFR mutations. The primary endpoint is overall survival; the secondary endpoints are progression-free survival, response rate, quality of life, and toxicity. We have planned to collect blood samples to identify different prognosis-related polymorphisms and to assess their sensitivity and specificity in the detection of EGFR and K-ras mutations with respect to histologic samples.

AB - We present the rationale and study design of the Tarceva Italian Lung Optimization trial phase III, multicenter, open-label, randomized trial on efficacy of second-line therapies in different subgroups of non-small-cell lung cancer (NSCLC) patients identified using molecular and clinical evaluations. To date, we can assume that advanced NSCLC epidermal growth factor receptor (EGFR)-mutated patients benefit from EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib, whereas their role in the treatment of patients who do not have EGFR mutations is controversial. The aim of this study is to assess whether it is possible to optimize second-line treatment in NSCLC patients with absence of EGFR mutations. Moreover, the predictive value of the K-ras mutation, EGFR protein expression, and EGFR gene copy number, as well as a smoking habit and histotype for determining a different effect of erlotinib compared with chemotherapy will be assessed in patients who do not have EGFR mutations. The primary endpoint is overall survival; the secondary endpoints are progression-free survival, response rate, quality of life, and toxicity. We have planned to collect blood samples to identify different prognosis-related polymorphisms and to assess their sensitivity and specificity in the detection of EGFR and K-ras mutations with respect to histologic samples.

UR - http://www.scopus.com/inward/record.url?scp=79959337566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959337566&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2011.03.008

DO - 10.1016/j.cllc.2011.03.008

M3 - Article

C2 - 21550561

AN - SCOPUS:79959337566

VL - 12

SP - 138

EP - 141

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 2

ER -